1. Home
  2. BDTX vs XGN Comparison

BDTX vs XGN Comparison

Compare BDTX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.38

Market Cap

104.0M

Sector

Health Care

ML Signal

N/A

Logo Exagen Inc.

XGN

Exagen Inc.

N/A

Current Price

$3.81

Market Cap

99.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BDTX
XGN
Founded
2014
2002
Country
United States
United States
Employees
N/A
220
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
99.5M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BDTX
XGN
Price
$1.38
$3.81
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
★ $11.00
$9.43
AVG Volume (30 Days)
★ 766.3K
706.4K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 130.71
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.77
Revenue Next Year
N/A
$9.52
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$2.59
52 Week High
$3.97
$9.22

Technical Indicators

Market Signals
Indicator
BDTX
XGN
Relative Strength Index (RSI) 34.73 28.65
Support Level N/A $2.90
Resistance Level $1.94 $5.13
Average True Range (ATR) 0.14 0.79
MACD -0.04 -0.34
Stochastic Oscillator 0.84 5.64

Price Performance

Historical Comparison
BDTX
XGN

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Share on Social Networks: